Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies

M. DeMagalhaes-Silverman, E. J. Bloom, A. Donnenberg, J. Lister, S. Pincus, Witold Rybka, E. D. Ball

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Between July 1991 and January 1994, 52 patients with hematologic malignancies underwent BMT using BU/CY2 as conditioning regimen. Median patient age was 38 years. Eleven patients underwent autologous BMT, 22 HLA-identical allogeneic BMT, and 19 patients underwent a MUD or an allogeneic mismatched BMT. GVHD prophylaxis was with cyclosporine/methylprednisone in 26 patients; T cell depletion was used in 15 patients. VOD was observed in 7.5% of patients, IP in 12%, seizures in 4%. The overall incidence of grade II-IV acute GVHD was 35%. Delayed platelet engraftment was observed in seven of 11 patients who underwent autologous BMT. Graft failure was seen in seven of 19 (37%) patients who underwent MUD or allogeneic mismatched BMT. Six of the seven patients received T cell depletion as GVHD prophylaxis. BU/CY2 transplantation from an unrelated or family-mismatched donor with T cell depletion is associated with a high incidence of graft failure.

Original languageEnglish (US)
Pages (from-to)329-333
Number of pages5
JournalBone Marrow Transplantation
Volume17
Issue number3
StatePublished - Mar 1 1996

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Toxicity of busulfan and cyclophosphamide (BU/CY<sub>2</sub>) in patients with hematologic malignancies'. Together they form a unique fingerprint.

  • Cite this

    DeMagalhaes-Silverman, M., Bloom, E. J., Donnenberg, A., Lister, J., Pincus, S., Rybka, W., & Ball, E. D. (1996). Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies. Bone Marrow Transplantation, 17(3), 329-333.